Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine

Background Our aim was to investigate the respective role of statistical methodology and patients' baseline characteristics in the selection of mutations included in genotypic resistance scores. Methods As an example, the FORUM database on didanosine including 1453 patients was used. We split t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2010-04, Vol.65 (4), p.752-760
Main Authors: Assoumou, Lambert, Houssaïni, Allal, Costagliola, Dominique, Flandre, Philippe
Format: Article
Language:English
Subjects:
Adult
Anti-HIV Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Biological and medical sciences
Canada
Comparative analysis
Didanosine - pharmacology
Drug Resistance, Viral
Female
France
Genotype
Genotype & phenotype
HIV-1 - drug effects
HIV-1 - genetics
Humans
International comparisons
Italy
Male
Medical sciences
Middle Aged
Mutation
Pharmacology. Drug treatments
RNA, Viral - genetics
Statistical methods
Treatment Outcome
United States
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Our aim was to investigate the respective role of statistical methodology and patients' baseline characteristics in the selection of mutations included in genotypic resistance scores. Methods As an example, the FORUM database on didanosine including 1453 patients was used. We split this population into four samples based on countries of enrolment (France n = 474, Italy n = 440, USA/Canada n = 219, others n = 320). We used both a continuous outcome measure (the viral load reduction at week 8) and a binary outcome measure (viral load decline at week 8 80% of the mutations are selected only once. The variability induced by the methodology varies from 49% to 56%, i.e. for a given data set ∼50% of the mutations are selected by at least two methods. Conclusions Baseline patient characteristics contribute more than the choice of statistical method to the variability of the mutations to be included in the genotypic resistance scores.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkq034